๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 18 Beijing 14 Shanghai 14 Chengdu 9 Fuzhou 6
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou18 Beijing14 Shanghai14 Chengdu9 Fuzhou6
All 36 locations
Target enrolment
to

Trials with a site in Beijing

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
NCT07668037Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2026-05-01
Not yet open
Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)
NCT07396116Soft Tissue Sarcoma (STS), Retroperitoneal Sarcoma, Immunotherapy, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
28
Beijing
2026-02-12
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Recruiting
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
NCT07212933Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy
Chinese PLA General Hospital
Phase 2
90
Beijing
2025-07-01
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
NCT07291921Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
Peking University People's Hospital
Observational
100
Beijing
2025-05-08
Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
NCT07166003Lung Cancer, Non-Small Cell, Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-04-20
Recruiting
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT06768307SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Active, closed
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
NCT06215677Colon Cancer, Mismatch Repair Deficiency, Immunotherapy
Peking Union Medical College Hospital
Phase 2
18
Beijing
2024-01-01
By invitation
Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults
NCT06777173Chronic Hepatitis b, Immunotherapy
Beijing Ditan Hospital
Not applicable
180
Beijing
2023-12-01
Recruiting
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06889649Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
Peking University First Hospital
Phase 2
30
Beijing
2019-01-01
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

10 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 14 studies
PhaseStudiesRecruitingShare
Phase 27550%
Observational5535.7%
Not applicable2014.3%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences43
Peking University People's Hospital22
Beijing Ditan Hospital10
Chinese PLA General Hospital11
jianming xu11
Peking Union Medical College Hospital10
Peking University Cancer Hospital & Institute11
Peking University First Hospital11
Seventh Medical Center of PLA General Hospital11
Yang Fan, MD10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.